To evaluate the potential for non-percutaneous routes of vaccine administration for measles to improve control.
How were the studies combined?
The studies were combined in a narrative discussion of study characteristics and results of individual trials. Data from the sets of trials for each type of intervention are presented in tables, as is a summary of the advantages and disadvantages of each route of administration of vaccine.
How were differences between studies investigated?
The authors do not state how differences between the studies were investigated.
Results of the review
For the intradermal route there were 7 studies with 1,063 participants (five studies had a control group who were given vaccine via percutaneous routes).
For the conjunctival route there were 4 small studies with 63 participants.
For the oral administration route there were 3 studies with 85 participants.
For the intranasal administration route, in children predominantly over 9 months of age, there were 7 studies with 922 participants.
For the intranasal administration route, in infants younger than 9 months of age, there were 4 studies with 270 participants.
For the aerosol administration route, in children predominantly over 9 months of age, there were 15 studies with 2,167 participants.
For the aerosol administration route, in infants younger than 9 months of age, there were 9 studies with 850 participants.
In the intradermal group, the percentage of seroresponse ranged from 10-100%. Needles and syringes and jet injectors had higher seroresponses (53-100%) while bifurcated needles, multiple puncture cylinders and needle implanted cylinders had the lowest seroresponses (10-74%).
In the conjunctival group, one study (2 participants) had a 100% seroresponse rate; the other 3 studies had 79% (29 participants), 10% (22 participants), and 0% (10 participants) seroresponse percentages. In the oral route group, studies showed ineffective results of 0%, 10%, 47% and 76% seroresponse.
Studies of the intranasal administration route, in children predominantly over 9 months of age, showed over 80% seroresponse, but others within the group found less than 20% seroresponse, variation sometimes being manifest within the same study.
Studies of the intranasal administration route, in infants younger than 9 months of age, reported seroresponses of 74-100% in two studies, but seroresponses of 0-10% in two other studies.
Studies of the aerosol administration route, in children predominantly over 9 months of age, showed a seroresponse between 0-100% compared with a seroresponse of 36-100% in control groups. High seroresponse rates were observed (93-100%) in four of the fifteen studies which directly sprayed into the mouth. A seroresponse rate of 86-100% was found in a further six trials which administered vaccine through a mask.
Studies of the aerosol administration route, in infants younger than 9 months of age, reported seroresponses of greater than 80% in seven of the nine studies at 3-6 months post-vaccination.
